Clinical Trials Browser

NIH × Lymphoproliferative Disorders × denileukin diftitox × Clear all

NCT00117845 2019-11-19

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

Phase 2 Terminated

17 enrolled 9 charts

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Leukemia-Lymphoma, Adult T-Cell